ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Amgen licenses Predix drugs

August 7, 2006 | APPEARED IN VOLUME 84, ISSUE 32

Amgen has joined forces with Predix Pharmaceuticals to develop S1P1 modulators for the treatment of autoimmune diseases. Amgen will pay Predix $20 million up front and could dole out an additional $287.5 million in milestone payments as the small-molecule drugs move through the clinic. The deal includes existing Predix preclinical compounds and new S1P1 modulators, and it calls for Amgen to handle clinical development and commercialization of product candidates. S1P1 modulators target a G-protein-coupled receptor that plays a role in immune system activation and cardiovascular function.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment